Approval

China approves Lilly's orforglipron, its first oral GLP-1 pill for weight management

Chinese regulators cleared orforglipron, a once-daily oral GLP-1 receptor agonist taken without food or water rules, for adult weight management. In ATTAIN-1 the top dose produced 12.4 kg average weight loss at 72 weeks, and 39.6% lost at least 15% versus 3.6% on placebo. Side effects were mostly mild gastrointestinal events during dose escalation.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Schematic animation of the GLP-1 receptor in a cell membrane, the small molecule orforglipron settling into a pocket at the top of the receptor, and the receptor switching on a G-protein signal inside the cell.
Orforglipron: a small molecule that switches on the GLP-1 receptor. Watch the mechanism animation on the orforglipron page.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call